Navigation Links
Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
Date:12/2/2010

third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments, domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and inve
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
2. Choices
3. Empowerment Competition
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
6. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
7. Amgen Announces Webcast of 2010 Third Quarter Financial Results
8. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
9. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
10. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
11. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Conn., March 16, 2011 Amarin Corporation plc (Nasdaq: ... on cardiovascular disease, today reported financial results for the ... The Company also provided an update on its progress ... product candidate, AMR101 for the treatment of elevated triglyceride ...
... announces that a new market research report is available ... Industry http://www.reportlinker.com/p098391/Global-Breast-Pumps-Industry.html ... in Thousands of Units by the following Product Segments: ... provides separate comprehensive analytics for the US, Canada, Europe, ...
Cached Medicine Technology:Amarin Reports Year-End and Q4 2010 Results 2Amarin Reports Year-End and Q4 2010 Results 3Amarin Reports Year-End and Q4 2010 Results 4Amarin Reports Year-End and Q4 2010 Results 5Amarin Reports Year-End and Q4 2010 Results 6Amarin Reports Year-End and Q4 2010 Results 7Amarin Reports Year-End and Q4 2010 Results 8Amarin Reports Year-End and Q4 2010 Results 9Global Breast Pumps Industry 2Global Breast Pumps Industry 3Global Breast Pumps Industry 4Global Breast Pumps Industry 5Global Breast Pumps Industry 6Global Breast Pumps Industry 7Global Breast Pumps Industry 8Global Breast Pumps Industry 9Global Breast Pumps Industry 10
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... Irvine, Calif., April 17, 2014 By discovering a ... immediately after a stroke, researchers at UC Irvine and ... therapies that may limit or prevent stroke-induced brain damage. ... the fourth-leading cause of death and primary reason for ... damaged in a stroke and lets blood-borne material into ...
(Date:4/17/2014)... the potential to ward off depression among retirees, particularly ... online in The Journals of Gerontology, Series ... the article " Internet Use and Depression Among Retired ... ," the authors report that Internet use reduced the ... their study sample. , Late-life depression affects between ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... in heart rate patterns provide information on how the ... long considered heart rate patterns to be important indicators ... as in labor and delivery. Now a new study ... predict the rate at which children develop through their ...
... November 15, 2007, Washington, DCEnsuring that everyone in the ... is not enough to drive the kind of reform ... released today by the Commonwealth Fund Commission on a ... for all, changing the way doctors and other health ...
... doctors for some prescriptions , , WEDNESDAY, Nov. 14 (HealthDay ... whether to allow certain drugs to be sold by ... officials listened to arguments for and against the proposal ... , But at the day,s end, the FDA officials ...
... a favourable clinical outcome in women with ovarian carcinoma, ... research published this week in the online open access ... family of peptide hormones, and the receptor GPR54 have ... tumours. In this study, researchers have shown that kisspeptin ...
... Nov. 14 The following is a,statement from ... Health,(TFAH):, "Trust for America,s Health (TFAH) urges ... Health and Human Services, Education and,Related Agencies Appropriations ... vital programs that:, -- Assist states, territories, ...
... Escalon Medical Corp.,(Nasdaq: ESMC ) today announced ... For the first quarter of fiscal 2008, the ... the $7,168,160, reported in the prior,year period. This decrease ... and Vascular business units, which decreased 3% and 2%,respectively, ...
Cached Medicine News:Health News:Fetal heart rate yields clues to children's later development 2Health News:Commonwealth Fund Commission issues reform recommendations for next president 2Health News:Commonwealth Fund Commission issues reform recommendations for next president 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Predicting the future in ovarian cancer 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 7
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... an open platform for clinical diagnostic applications. The ... of 75, 100, 150 and 200 cm ... laboratory space and throughput requirements. Tecan will focus ... new applications and to evolve the quality, safety ...
... For maximum productivity, and proven reliability, ... compact, fully automatic cell washing and ... fast 80-second wash cycle for stat ... controls, and standardized, reproducible procedures. High ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
Medicine Products: